Vitamin D. Biology, Actions, and Clinical Implications.

Osteoporosis: Fourth Edition

Volumn , Issue , 2013, Pages 283-328

  Feldman, David ^a   Krishnan, Aruna V ^a   Swami, Srilatha ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1 hydroxylase; 25(OH)D serum levels; 25 hydroxylation; Calcitonin; Calcium; Cancer; ChIP analysis; Coactivators; DBD; DBP; Dietary sources; Food fortification; Genomic response; Heterodimerization; Hinge region; Hyperparathyroidism; Institute of Medicine (IOM) Report; Kidney; LBD; Megalin gene; Osteoclastogenesis; Parathyroid glands; Photobiology; Skin pigmentation; VDR; VDRKO; Vitamin D; WINAC

Indexed keywords

EID: 84903080107     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-415853-5.00013-3     Document Type: Chapter

References (410)

1. Christakos S., DeLuca H.F. Minireview: vitamin D: is there a role in extraskeletal health?. Endocrinology 2011, 152:2930-2936.
2. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007, 7:684-700.
3. Haussler M.R., Jurutka P.W., Mizwicki M., Norman A.W. Vitamin D receptor (VDR)-mediated actions of 1alpha,25(OH)vitamin D: genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab 2011, 25:543-559.
4. Krishnan A.V., Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011, 51:311-336.
5. Malloy P.J., Feldman D. Genetic disorders and defects in vitamin D action. Endocrinol Metab Clin North Am 2010, 39:333-346.
6. Orlov I., Rochel N., Moras D., Klaholz B.P. Structure of the full human RXR/VDR nuclear receptor heterodimer complex with its DR3 target DNA. EMBO J 2012, 31:291-300.
7. Pike J.W., Meyer M.B. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin North Am 2010, 39:255-269.
8. Pike J.W., Meyer M.B., Bishop K.A. Regulation of target gene expression by the vitamin D receptor - an update on mechanisms. Rev Endocr Metab Disord 2012, 13:45-55.
9. Feldman D., Pike J.W., Adams J.S. Vitamin D 2011, Elsevier/Academic Press, San Diego. 3rd ed.
10. Jones G., Prosser D.E. The activating enzymes of vitamin D metabolism. Vitamin D 2011, 23-42. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
11. Heaney R.P., Recker R.R., Grote J., Horst R.L., Armas L.A. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab 2011, 96:E447-E452.
12. Holick M.F. McCollum Award Lecture, 1994: vitamin D - new horizons for the 21st century. Am J Clin Nutr 1994, 60:619-630.
13. Kodicek E. The story of vitamin D, from vitamin to hormone. Lancet 1974, 1:325-329.
14. DeLuca H.F. Historical perspective. Vitamin D 2005, 3-12. Elsevier Academic Press, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
15. O'Riordan J.L. Rickets in the 17th century. J Bone Miner Res 2006, 21:1506-1510.
16. DeLuca H.F. Historical overview of vitamin D. Vitamin D 2011, 3-12. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
17. Bikle D.D. Vitamin D and bone mineral metabolism in hepatogastrointestinal diseases. Vitamin D 2011, Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
18. Beydoun M.A., Boueiz A., Shroff M.R., Beydoun H.A., Wang Y., Zonderman A.B. Associations among 25-hydroxyvitamin D, diet quality, and metabolic disturbance differ by adiposity in adults in the United States. J Clin Endocrinol Metab 2010, 95:3814-3827.
19. Lo C.W., Paris P.W., Clemens T.L., Nolan J., Holick M.F. Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes. Am J Clin Nutr 1985, 42:644-649.
20. Thacher T.D., Fischer P.R., Strand M.A., Pettifor J.M. Nutritional rickets around the world: causes and future directions. Ann Trop Paediatr 2006, 26:1-16.
21. Wharton B., Bishop N. Rickets. Lancet 2003, 362:1389-1400.
22. Holick M.F. Photobiology of vitamin D. Vitamin D 2011, 13-22. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
23. Demay M.B. The hair cycle and vitamin D receptor. Arch Biochem Biophys 2012, 523:19-21.
24. Courtois S.J., Segaert S., Degreef H., Bouillon R., Garmyn M. Ultraviolet B suppresses vitamin D receptor gene expression in keratinocytes. Biochem Biophys Res Commun 1998, 246:64-69.
25. Matsuoka L.Y., Wortsman J., Chen T.C., Holick M.F. Compensation for the interracial variance in the cutaneous synthesis of vitamin D. J Lab Clin Med 1995, 126:452-457.
26. Loomis W.F. Skin-pigment regulation of vitamin-D biosynthesis in man. Science 1967, 157:501-506.
27. Holick M.F., MacLaughlin J.A., Doppelt S.H. Regulation of cutaneous previtamin D3 photosynthesis in man: skin pigment is not an essential regulator. Science 1981, 211:590-593.
28. Schwartz G.G., Chen T.C. Vitamin D, sunlight, and the natural history of prostate cancer. Vitamin D 2005, 1599-1615. Elsevier, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
29. Garland F.C., Garland C.F., Gorham E.D., Young J.F. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 1990, 19:614-622.
30. Grant W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94:1867-1875.
31. Mortimer E.A., Monson R.R., MacMahon B. Reduction in mortality from coronary heart disease in men residing at high altitude. N Engl J Med 1977, 296:581-585.
32. Kurtzke J.F. Multiple sclerosis in time and space - geographic clues to cause. J Neurovirol 2000, 6(Suppl. 2):S134-S140.
33. Wei M.Y., Giovannucci E.L. Vitamin D and multiple health outcomes in the Harvard cohorts. Mol Nutr Food Res 2010, 54:1114-1126.
34. Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004, 80:1678S-1688S.
35. Wolpowitz D., Gilchrest B.A. The vitamin D questions: how much do you need and how should you get it?. J Am Acad Dermatol 2006, 54:301-317.
36. U.S.Department of Health and Human Services Report on Carcinogens, 11th Edition 2005, Public Health Service, National Toxicology Program, Washington.
37. Lucas R., McMichael T., Smith W., Armstrong B. Solar ultraviolet radiation: global burden of disease from solar ultraviolet radiation 2006, World Health Organization, Geneva.
38. Gandini S., Sera F., Cattaruzza M.S., Pasquini P., Picconi O., Boyle P., et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005, 41:45-60.
39. Mason R.S., Sequeira V.B., Dixon K.M., Gordon-Thomson C., Pobre K., Dilley A., et al. Photoprotection by 1alpha,25-dihydroxyvitamin D and analogs: further studies on mechanisms and implications for UV-damage. J Steroid Biochem Mol Biol 2010, 121:164-168.
40. Tang J.Y., Fu T., Leblanc E., Manson J.E., Feldman D., Linos E., et al. Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. J Clin Oncol 2011, 29:3078-3084.
41. U.S.Department of Agriculture ARS USDA Nutrient Database for Standard Reference, Release 16 2003, Beltsville, MD.
42. 2006 National Institute of Health, Office of Dietary Supplements. "Dietary Supplements Fact Sheet: Vitamin D." Bethesda, MD.
43. Calvo M.S., Whiting S.J., Barton C.N. Vitamin D fortification in the United States and Canada: current status and data needs. Am J Clin Nutr 2004, 80:1710S-1716S.
44. Natri A.M., Salo P., Vikstedt T., Palssa A., Huttunen M., Karkkainen M.U., et al. Bread fortified with cholecalciferol increases the serum 25-hydroxyvitamin D concentration in women as effectively as a cholecalciferol supplement. J Nutr 2006, 136:123-127.
45. Ross A.C., Manson J.E., Abrams S.A., Aloia J.F., Brannon P.M., Clinton S.K., et al. The (2011). report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011, 96:53-58.
46. Stolzenberg-Solomon R.Z., Jacobs E.J., Arslan A.A., Qi D., Patel A.V., Helzlsouer K.J., et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010, 172:81-93.
47. Weinstein S.J., Stolzenberg-Solomon R.Z., Kopp W., Rager H., Virtamo J., Albanes D. Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study. Cancer Res 2012, 72:1190-1198.
48. Wolpin B.M., Ng K., Bao Y., Kraft P., Stampfer M.J., Michaud D.S., et al. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2012, 21:82-91.
49. Heaney R.P., Holick M.F. Why the IOM recommendations for vitamin D are deficient. J Bone Miner Res 2011, 26:455-457.
50. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., Gordon C.M., Hanley D.A., Heaney R.P., et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:1911-1930.
51. Daiger S.P., Schanfield M.S., Cavalli-Sforza L.L. Group-specific component (Gc) proteins bind vitamin D and 25-hydroxyvitamin D. Proc Natl Acad Sci U S A 1975, 72:2076-2080.
52. Cleve H., Constans J. The mutants of the vitamin-D-binding protein: more than 120 variants of the GC/DBP system. Vox Sang 1988, 54:215-225.
53. Cavalli-Sforza L.L., Menozzi P., Piazza A. The History and Geography of Human Genes 1994, Princeton University Press, Princeton, NJ.
54. Bouillon R. The vitamin D binding protein DBP. Vitamin D 2011, 57-72. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
55. Laing C.J., Cooke N.E. Vitamin D binding protein. Vitamin D 2005, 117-134. Elsevier, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
56. Haddad J.G., Matsuoka L.Y., Hollis B.W., Hu Y.Z., Wortsman J. Human plasma transport of vitamin D after its endogenous synthesis. J Clin Invest 1993, 91:2552-2555.
57. Bouillon R., Allewaert K., Xiang D.Z., Tan B.K., van Baelen H. Vitamin D analogs with low affinity for the vitamin D binding protein: enhanced in vitro and decreased in vivo activity. J Bone Miner Res 1991, 6:1051-1057.
58. Berg J.P. Vitamin D-binding protein prevents vitamin D deficiency and presents vitamin D for its renal activation. Eur J Endocrinol 1999, 141:321-322.
59. Chun R.F., Lauridsen A.L., Suon L., Zella L.A., Pike J.W., Modlin R.L., et al. Vitamin D-binding protein directs monocyte responses to 25-hydroxy- and 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab 2010, 95:3368-3376.
60. Sinotte M., Diorio C., Berube S., Pollak M., Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 2009, 89:634-640.
61. Wang T.J., Zhang F., Richards J.B., Kestenbaum B., van Meurs J.B., Berry D., et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010, 376:180-188.
62. Willnow T.E., Nykjaer A. Endocytic pathways for 25-(OH) vitamin D3. Vitamin D 2005, 153-163. Elsevier, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
63. Nykjaer A., Dragun D., Walther D., Vorum H., Jacobsen C., Herz J., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999, 96:507-515.
64. Willnow T.E., Nykjaer A. Cellular uptake of steroid carrier proteins - mechanisms and implications. Mol Cell Endocrinol 2010, 316:93-102.
65. Lisse T.S., Hewison M., Adams J.S. Hormone response element binding proteins: novel regulators of vitamin D and estrogen signaling. Steroids 2011, 76:331-339.
66. Hollis B.W. Assessment of vitamin D status and definition of a normal circulating range of 25-hydroxyvitamin D. Curr Opin Endocrinol Diabetes Obes 2008, 15:489-494.
67. Binkley N., Krueger D.C., Morgan S., Wiebe D. Current status of clinical 25-hydroxyvitamin D measurement: an assessment of between-laboratory agreement. Clin Chim Acta 2010, 411:1976-1982.
68. Kleerekoper M., Schleicher R.L., Eisman J., Bouillon R., Singh R.J., Holick M.F. Clinical applications for vitamin D assays: what is known and what is wished for. Clin Chem 2011, 57:1227-1232.
69. Bouillon R. How to define optimal vitamin D status. Vitamin D 2011, 1067-1088. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
70. Manson J.E., Bassuk S.S., Lee I.M., Cook N.R., Albert M.A., Gordon D., et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012, 33:159-171.
71. Okereke O.I., Manson J.E. The VITamin D and OmegA-3 TriaL (VITAL): Rationale trial. Vitamin D 2011, 2043-2056. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
72. Heaney R.P., Davies K.M., Chen T.C., Holick M.F., Barger-Lux M.J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003, 77:204-210.
73. Dawson-Hughes B., Heaney R.P., Holick M.F., Lips P., Meunier P.J., Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005, 16:713-716.
74. Armas L.A., Hollis B.W., Heaney R.P. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004, 89:5387-5391.
75. Heaney R.P. The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 2005, 97:13-19.
76. Jackson R.D., LaCroix A.Z., Gass M., Wallace R.B., Robbins J., Lewis C.E., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006, 354:669-683.
77. Towler D.A. Vitamin D: cardiovascular effects and vascular calcification. Vitamin D 2011, 1403-1428. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
78. Shor R., Tirosh A., Shemesh L., Krakover R., Bar Chaim A., Mor A., et al. 25 hydroxyvitamin D levels in patients undergoing coronary artery catheterization. Eur J Intern Med 2012, 23:470-473.
79. Holick M.F. Vitamin D deficiency in 2010: health benefits of vitamin D and sunlight: a D-bate. Nat Rev Endocrinol 2011, 7:73-75.
80. Looker A.C., Dawson-Hughes B., Calvo M.S., Gunter E.W., Sahyoun N.R. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 2002, 30:771-777.
81. Grover S.R., Morley R. Vitamin D deficiency in veiled or dark-skinned pregnant women. Med J Aust 2001, 175:251-252.
82. Nozza J.M., Rodda C.P. Vitamin D deficiency in mothers of infants with rickets. Med J Aust 2001, 175:253-255.
83. Calvo M.S., Whiting S.J. Public health strategies to overcome barriers to optimal vitamin D status in populations with special needs. J Nutr 2006, 136:1135-1139.
84. Thomas M.K., Lloyd-Jones D.M., Thadhani R.I., Shaw A.C., Deraska D.J., Kitch B.T., et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998, 338:777-783.
85. LeBoff M.S., Kohlmeier L., Hurwitz S., Franklin J., Wright J., Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999, 281:1505-1511.
86. Chapuy M.C., Arlot M.E., Delmas P.D., Meunier P.J. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994, 308:1081-1082.
87. Chapuy M.C., Pamphile R., Paris E., Kempf C., Schlichting M., Arnaud S., et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002, 13:257-264.
88. Dawson-Hughes B., Harris S.S., Krall E.A., Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997, 337:670-676.
89. Trivedi D.P., Doll R., Khaw K.T. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003, 326:469.
90. Pettifor J.M., Prentice A. The role of vitamin D in paediatric bone health. Best Pract Res Clin Endocrinol Metab 2011, 25:573-584.
91. Abrams S.A. Calcium and vitamin D requirements for optimal bone mass during adolescence. Curr Opin Clin Nutr Metab Care 2011, 14:605-609.
92. Rosen H., Reshef A., Maeda N., Lippoldt A., Shpizen S., Triger L., et al. Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene. J Biol Chem 1998, 273:14805-14812.
93. Cheng J.B., Motola D.L., Mangelsdorf D.J., Russell D.W. De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J Biol Chem 2003, 278:38084-38093.
94. Strushkevich N., Usanov S.A., Plotnikov A.N., Jones G., Park H.W. Structural analysis of CYP2R1 in complex with vitamin D3. J Mol Biol 2008, 380:95-106.
95. Cheng J.B., Levine M.A., Bell N.H., Mangelsdorf D.J., Russell D.W. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 2004, 101:7711-7715.
96. Jones G., Prosser D.E., Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys 2011, 523:9-18.
97. 3 1alpha-hydroxylase and vitamin D synthesis. Science 1997, 277:1827-1830.
98. Fu G.K., Lin D., Zhang M.Y., Bikle D.D., Shackleton C.H., Miller W.L., et al. Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol 1997, 11:1961-1970.
99. 3 1(alpha)- hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 1998, 338:653-661.
100. Labuda M., Morgan K., Glorieux F.H. Mapping autosomal recessive vitamin D dependency type I to chromosome 12q14 by linkage analysis. Am J Hum Genet 1990, 47:28-36.
101. Labuda M., Fujiwara T.M., Ross M.V., Morgan K., Garcia-Heras J., Ledbetter D.H., et al. Two hereditary defects related to vitamin D metabolism map to the same region of human chromosome 12q13-14. J Bone Miner Res 1992, 7:1447-1453.
102. Kim C.J., Kaplan L.E., Perwad F., Huang N., Sharma A., Choi Y., et al. Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency. J Clin Endocrinol Metab 2007, 92:3177-3182.
103. Adams J.S., Hewison M. Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. Arch Biochem Biophys 2012, 523:95-102.
104. Bell N.H. Renal and nonrenal 25-hydroxyvitamin D-1alpha-hydroxylases and their clinical significance. J Bone Miner Res 1998, 13:350-353.
105. Howard G.A., Turner R.T., Sherrard D.J., Baylink D.J. Human bone cells in culture metabolize 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. J Biol Chem 1981, 256:7738-7740.
106. Adams J.S., Sharma O.P., Gacad M.A., Singer F.R. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest 1983, 72:1856-1860.
107. Smith S.J., Rucka A.K., Berry J.L., Davies M., Mylchreest S., Paterson C.R., et al. Novel mutations in the 1alpha-hydroxylase (P450c1) gene in three families with pseudovitamin D-deficiency rickets resulting in loss of functional enzyme activity in blood-derived macrophages. J Bone Miner Res 1999, 14:730-739.
108. Cross H.S., Peterlik M., Reddy G.S., Schuster I. Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D3-1alpha-hydroxylase activity and regulation of side-chain metabolism. J Steroid Biochem Mol Biol 1997, 62:21-28.
109. Weisman Y., Harell A., Edelstein S., David M., Spirer Z., Golander A. 1 alpha, 25-Dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in vitro synthesis by human decidua and placenta. Nature 1979, 281:317-319.
110. Townsend K., Evans K.N., Campbell M.J., Colston K.W., Adams J.S., Hewison M. Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J Steroid Biochem Mol Biol 2005, 97:103-109.
111. Schwartz G.G., Whitlatch L.W., Chen T.C., Lokeshwar B.L., Holick M.F. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25- hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 1998, 7:391-395.
112. Dusso A., Gonzalez E.A., Martin K.J. Vitamin D in chronic kidney disease. Best Pract Res Clin Endocrinol Metab 2011, 25:647-655.
113. Martin A., David V., Quarles L.D. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012, 92:131-155.
114. Murayama A., Takeyama K., Kitanaka S., Kodera Y., Kawaguchi Y., Hosoya T., et al. Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals. Endocrinology 1999, 140:2224-2231.
115. Kong X.F., Zhu X.H., Pei Y.L., Jackson D.M., Holick M.F. Molecular cloning, characterization, and promoter analysis of the human 25-hydroxyvitamin D3-1alpha-hydroxylase gene. Proc Natl Acad Sci U S A 1999, 96:6988-6993.
116. Beckerman P., Silver J. Vitamin D and the parathyroid. Am J Med Sci 1999, 317:363-369.
117. Henry H.L. Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab 2011, 25:531-541.
118. Kim M.S., Kondo T., Takada I., Youn M.Y., Yamamoto Y., Takahashi S., et al. DNA demethylation in hormone-induced transcriptional derepression. Nature 2009, 461:1007-1012.
119. Zierold C., Nehring J.A., DeLuca H.F. Nuclear receptor 4A2 and C/EBPbeta regulate the parathyroid hormone-mediated transcriptional regulation of the 25-hydroxyvitamin D3-1alpha-hydroxylase. Arch Biochem Biophys 2007, 460:233-239.
120. Wortsman J., Haddad J.G., Posillico J.T., Brown E.M. Primary hyperparathyroidism with low serum 1,25-dihydroxyvitamin D levels. J Clin Endocrinol Metab 1986, 62:1305-1308.
121. 2+ sensing receptor from bovine parathyroid. Nature 1993, 366:575-580.
122. Riccardi D., Park J., Lee W., Gamba G., Brown E.M., Hebert S. Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. Proc Natl Acad Sci U S A 1995, 92:131-135.
123. Chattopadhyay N., Mithal A., Brown E.M. The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocr Rev 1996, 17:289-307.
124. Slatopolsky E., Dusso A., Brown A.J. The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Am J Med Sci 1999, 317:370-376.
125. Segawa H., Onitsuka A., Furutani J., Kaneko I., Aranami F., Matsumoto N., et al. Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development. Am J Physiol Renal Physiol 2009, 297:F671-F678.
126. Carpenter T.O. The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 2012, 30:1-9.
127. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
128. Tsujikawa H., Kurotaki Y., Fujimori T., Fukuda K., Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003, 17:2393-2403.
129. Ichikawa S., Imel E.A., Kreiter M.L., Yu X., Mackenzie D.S., Sorenson A.H., et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007, 117:2684-2691.
130. Takeyama K., Kato S. The vitamin D3 1alpha-hydroxylase gene and its regulation by active vitamin D3. Biosci Biotechnol Biochem 2011, 75:208-213.
131. Jaeger P., Jones W., Clemens T.L., Hayslett J.P. Evidence that calcitonin stimulates 1,25-dihydroxyvitamin D production and intestinal absorption of calcium in vivo. J Clin Invest 1986, 78:456-461.
132. Econs M.J., Lobaugh B., Drezner M.K. Normal calcitonin stimulation of serum calcitriol in patients with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 1992, 75:408-411.
133. Nesbitt T., Lobaugh B., Drezner M.K. Calcitonin stimulation of renal 25-hydroxyvitamin D-1 alpha-hydroxylase activity in hypophosphatemic mice. Evidence that the regulation of calcitriol production is not universally abnormal in X-linked hypophosphatemia. J Clin Invest 1987, 79:15-19.
134. Shinki T., Ueno Y., DeLuca H.F., Suda T. Calcitonin is a major regulator for the expression of renal 25- hydroxyvitamin D3-1alpha-hydroxylase gene in normocalcemic rats. Proc Natl Acad Sci U S A 1999, 96:8253-8258.
135. Silver J., Levi R. Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease. Kidney Int Suppl 2005, S8-S12.
136. Slatopolsky E., Brown A., Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999, 73:S14-S19.
137. Hewison M., Zehnder D., Chakraverty R., Adams J.S. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol Cell Endocrinol 2004, 215:31-38.
138. Young M.V., Schwartz G.G., Wang L., Jamieson D.P., Whitlatch L.W., Flanagan J.N., et al. The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 2004, 25:967-971.
139. Wang L., Flanagan J.N., Whitlatch L.W., Jamieson D.P., Holick M.F., Chen T.C. Regulation of 25-hydroxyvitamin D-1alpha-hydroxylase by epidermal growth factor in prostate cells. J Steroid Biochem Mol Biol 2004, 89-90:127-130.
140. Vantieghem K., Kissmeyer A.M., De Haes P., Bouillon R., Segaert S. UVB-induced production of 1,25-dihydroxyvitamin D3 and vitamin D activity in human keratinocytes pretreated with a sterol delta7-reductase inhibitor. J Cell Biochem 2006, 98:81-92.
141. Wu S., Ren S., Nguyen L., Adams J.S., Hewison M. Splice variants of the CYP27b1 gene and the regulation of 1,25-dihydroxyvitamin D3 production. Endocrinology 2007, 148:3410-3418.
142. Cusano N.E., Thys-Jacobs S., Bilezikian J.P. Hypercalcemia due to vitamin D toxicity. Vitamin D 2011, 1381-1402. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
143. van Leeuwen J.P.T.M., van Driel M., Feldman D., Munoz A. Vitamin D: cancer and differentiation. Vitamin D 2011, 1591-1624. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
144. Swami S., Krishnan A.V., Wang J.Y., Jensen K., Horst R., Albertelli M.A., et al. Dietary vitamin D3 and 1,25-dihydroxyvitamin D3 (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology 2012, 153:2576-2587.
145. St-Arnaud R. CYP42A1: structure, function, and physiological role. Vitamin D 2011, 43-56. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman., J.W. Pike, J.S. Adams (Eds.).
146. Petkovich M., Jones G. CYP24A1 and kidney disease. Curr Opin Nephrol Hypertens 2011, 20:337-344.
147. St-Arnaud R. Targeted inactivation of vitamin D hydroxylases in mice. Bone 1999, 25:127-129.
148. Hahn C.N., Baker E., Laslo P., May B.K., Omdahl J.L., Sutherland G.R. Localization of the human vitamin D 24-hydroxylase gene (CYP24) to chromosome 20q13.2>q13.3. Cytogenet Cell Genet 1993, 62:192-193.
149. 3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim Biophys Acta 1995, 1263:1-9.
150. Omdhal J., May B. The 25-hydroxyvitamin D 24-hydroxylase. Vitamin D 2005, 84-104. Elsevier, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
151. 3 24-hydroxylase gene. J Biol Chem 1994, 269:10545-10550.
152. Malloy P.J., Pike J.W., Feldman D. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr Rev 1999, 20:156-188.
153. Malloy P.J., Tiosano D., Feldman D. Hereditary 1,25-Dihydroxyvitamin D-resistant rickets. Vitamin D 2011, 1197-1232. Elsevier/Academic Press, San Diego, Vitamin D. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
154. Shigematsu T., Horiuchi N., Ogura Y., Miyahara T., Suda T. Human parathyroid hormone inhibits renal 24-hydroxylase activity of 25-hydroxyvitamin D3 by a mechanism involving adenosine 3',5'-monophosphate in rats. Endocrinology 1986, 118:1583-1589.
155. Yang W., Hyllner S.J., Christakos S. Interrelationship between signal transduction pathways and 1,25(OH)2D3 in UMR106 osteoblastic cells. Am J Physiol Endocrinol Metab 2001, 281:E162-E170.
156. Huening M., Yehia G., Molina C.A., Christakos S. Evidence for a regulatory role of inducible cAMP early repressor in protein kinase A-mediated enhancement of vitamin D receptor expression and modulation of hormone action. Mol Endocrinol 2002, 16:2052-2064.
157. Perwad F., Zhang M.Y., Tenenhouse H.S., Portale A.A. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007, 293:F1577-F1583.
158. Shimada T., Yamazaki Y., Takahashi M., Hasegawa H., Urakawa I., Oshima T., et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005, 289:F1088-F1095.
159. Beckman M.J., Goff J.P., Reinhardt T.A., Beitz D.C., Horst R.L. In Vivo regulation of rat intestinal 24-hydroxylase: potential new role of calcitonin. J Clin Endocrinol Metab 1994, 135:1951-1955.
160. Peehl D.M., Seto E., Hsu J.Y., Feldman D. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol 2002, 168:1583-1588.
161. Loose D.S., Kan P.B., Hirst M.A., Marcus R.A., Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 1983, 71:1495-1499.
162. Ly L.H., Zhao X.Y., Holloway L., Feldman D. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999, 140:2071-2076.
163. Swami S., Krishnan A.V., Peehl D.M., Feldman D. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D(3) in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol 2005, 12:12.
164. Zhang Q., Kanterewicz B., Buch S., Petkovich M., Parise R., Beumer J., et al. CYP24 inhibition preserves 1alpha,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. Mol Cell Endocrinol 2012, 355:153-161.
165. Wang J.Y., Swami S., Krishnan A.V., Feldman D. Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer. Prostate 2012, 72:1628-1637.
166. Schlingmann K.P., Kaufmann M., Weber S., Irwin A., Goos C., John U., et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 2011, 365:410-421.
167. Castillo L., Tanaka Y., DeLuca H.F., Ikekawa N. On the physiological role of 1,24,25-trihydroxyvitamin D3. Miner Electrolyte Metab 1978, 1:198-207.
168. Siu-Caldera M.L., Zou L., Ehrlich M.G., Schwartz E.R., Ishizuka S., Reddy G.S. Human osteoblasts in culture metabolize both 1 alpha, 25-dihydroxyvitamin D3 and its precursor 25-hydroxyvitamin D3 into their respective lactones. Endocrinology 1995, 136:4195-4203.
169. Prosser D.E., Kaufmann M., O'Leary B., Byford V., Jones G. Single A326G mutation converts human CYP24A1 from 25-OH-D3-24-hydroxylase into -23-hydroxylase, generating 1alpha,25-(OH)2D3-26,23-lactone. Proc Natl Acad Sci U S A 2007, 104:12673-12678.
170. Bischof M.G., Siu-Caldera M.L., Weiskopf A., Vouros P., Cross H.S., Peterlik M., et al. Differentiation-related pathways of 1 alpha,25-dihydroxycholecalciferol metabolism in human colon adenocarcinoma-derived Caco-2 cells: production of 1 alpha,25-dihydroxy-3epi-cholecalciferol. Exp Cell Res 1998, 241:194-201.
171. Molnar F., Sigueiro R., Sato Y., Araujo C., Schuster I., Antony P., et al. 1alpha,25(OH)2-3-epi-vitamin D3, a natural physiological metabolite of vitamin D3: its synthesis, biological activity and crystal structure with its receptor. PLoS One 2011, 6:e18124.
172. McDonnell D.P., Mangelsdorf D.J., Pike J.W., Haussler M.R., O'Malley B.W. Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. Science 1987, 235:1214-1217.
173. Baker A.R., McDonnell D.P., Hughes M., Crisp T.M., Mangelsdorf D.J., Haussler M.R., et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A 1988, 85:3294-3298.
174. Whitfield G.K., Jurutka P.W., Haussler C.A., Hsieh J.-C., Barthel T.K., Jacobs E.T., et al. Nuclear vitamin D receptor: structure-function, molecular control of gene transcription and novel bioactions. Vitamin D 2005, 219-262. Elsevier, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
175. Smith C.L., O'Malley B.W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004, 25:45-71.
176. Rochel N., Wurtz J.M., Mitschler A., Klaholz B., Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 2000, 5:173-179.
177. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., et al. Differential ligand activation of receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277:1508-1510.
178. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95:927-937.
179. Vanhooke J.L., Benning M.M., Bauer C.B., Pike J.W., DeLuca H.F. Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide. Biochemistry 2004, 43:4101-4110.
180. Rochel N., Ciesielski F., Godet J., Moman E., Roessle M., Peluso-Iltis C., et al. Common architecture of nuclear receptor heterodimers on DNA direct repeat elements with different spacings. Nat Struct Mol Biol 2011, 18:564-570.
181. Makishima M., Lu T.T., Xie W., Whitfield G.K., Domoto H., Evans R.M., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
182. Jurutka P.W., Bartik L., Whitfield G.K., Mathern D.R., Barthel T.K., Gurevich M., et al. Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J Bone Miner Res 2007, 22(Suppl. 2):V2-V10.
183. Bartik L., Whitfield G.K., Kaczmarska M., Lowmiller C.L., Moffet E.W., Furmick J.K., et al. Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. J Nutr Biochem 2010, 21:1153-1161.
184. Haussler M.R., Haussler C.A., Bartik L., Whitfield G.K., Hsieh J.C., Slater S., et al. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr Rev 2008, 66:S98-S112.
185. Schmidt D.R., Holmstrom S.R., Fon Tacer K., Bookout A.L., Kliewer S.A., Mangelsdorf D.J. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J Biol Chem 2010, 285:14486-14494.
186. Jurutka P.W., Hsieh J.C., MacDonald P.N., Terpening C.M., Haussler C.A., Haussler M.R., et al. Phosphorylation of serine 208 in the human vitamin D receptor. The predominant amino acid phosphorylated by casein kinase II, in vitro, and identification as a significant phosphorylation site in intact cells. J Biol Chem 1993, 268:6791-6799.
187. Jurutka P.W., Hsieh J.C., Nakajima S., Haussler C.A., Whitfield G.K., Haussler M.R. Human vitamin D receptor phosphorylation by casein kinase II at Ser-208 potentiates transcriptional activation. Proc Natl Acad Sci U S A 1996, 93:3519-3524.
188. Arriagada G., Paredes R., Olate J., van Wijnen A., Lian J.B., Stein G.S., et al. Phosphorylation at serine 208 of the 1alpha,25-dihydroxy Vitamin D3 receptor modulates the interaction with transcriptional coactivators. J Steroid Biochem Mol Biol 2007, 103:425-429.
189. Barletta F., Freedman L.P., Christakos S. Enhancement of VDR-mediated transcription by phosphorylation: correlation with increased interaction between the VDR and DRIP205, a subunit of the VDR-interacting protein coactivator complex. Mol Endocrinol 2002, 16:301-314.
190. Solomon C., White J.H., Kremer R. Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating human retinoid X receptor alpha. J Clin Invest 1999, 103:1729-1735.
191. Masuyama H., MacDonald P.N. Proteasome-mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the AF-2 domain of VDR. J Cell Biochem 1998, 71:429-440.
192. Malloy P.J., Feldman D. Inactivation of the human vitamin D receptor by caspase-3. Endocrinology 2009, 150:679-686.
193. Miyamoto K., Kesterson R.A., Yamamoto H., Taketani Y., Nishiwaki E., Tatsumi S., et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol 1997, 11:1165-1179.
194. Crofts L.A., Hancock M.S., Morrison N.A., Eisman J.A. Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc Natl Acad Sci U S A 1998, 95:10529-10534.
195. Lee T.H., Pelletier J. Functional characterization of WT1 binding sites within the human vitamin D receptor gene promoter. Physiol Genomics 2001, 7:187-200.
196. Zella L.A., Kim S., Shevde N.K., Pike J.W. Enhancers located within two introns of the vitamin D receptor gene mediate transcriptional autoregulation by 1,25-dihydroxyvitamin D3. Mol Endocrinol 2006, 20:1231-1247.
197. Kommagani R., Caserta T.M., Kadakia M.P. Identification of vitamin D receptor as a target of p63. Oncogene 2006, 25:3745-3751.
198. Maruyama R., Aoki F., Toyota M., Sasaki Y., Akashi H., Mita H., et al. Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res 2006, 66:4574-4583.
199. Yamamoto H., Miyamoto K., Li B., Taketani Y., Kitano M., Inoue Y., et al. The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine. J Bone Miner Res 1999, 14:240-247.
200. Arai H., Miyamoto K.I., Yoshida M., Yamamoto H., Taketani Y., Morita K., et al. The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J Bone Miner Res 2001, 16:1256-1264.
201. Hsieh J.C., Shimizu Y., Minoshima S., Shimizu N., Haussler C.A., Jurutka P.W., et al. Novel nuclear localization signal between the two DNA-binding zinc fingers in the human vitamin D receptor. J Cell Biochem 1998, 70:94-109.
202. Luo Z., Rouvinen J., Maenpaa P.H. A peptide C-terminal to the second Zn finger of human vitamin D receptor is able to specify nuclear localization. Eur J Biochem 1994, 223:381-387.
203. Michigami T., Suga A., Yamazaki M., Shimizu C., Cai G., Okada S., et al. Identification of amino acid sequence in the hinge region of human vitamin D receptor that transfers a cytosolic protein to the nucleus. J Biol Chem 1999, 274:33531-33538.
204. Racz A., Barsony J. Hormone-dependent translocation of vitamin D receptors is linked to transactivation. J Biol Chem 1999, 274:19352-19360.
205. Barsony J., Prufer K. Vitamin D receptor and retinoid X receptor interactions in motion. Vitam Horm 2002, 65:345-376.
206. Peleg S., Nguyen C.V. The importance of nuclear import in protection of the vitamin D receptor from polyubiquitination and proteasome-mediated degradation. J Cell Biochem 2010, 110:926-934.
207. Arriagada G., Henriquez B., Moena D., Merino P., Ruiz-Tagle C., Lian J.B., et al. Recruitment and subnuclear distribution of the regulatory machinery during 1alpha,25-dihydroxy vitamin D3-mediated transcriptional upregulation in osteoblasts. J Steroid Biochem Mol Biol 2010, 121:156-158.
208. Prufer K., Barsony J. Retinoid x receptor dominates the nuclear import and export of the unliganded vitamin d receptor. Mol Endocrinol 2002, 16:1738-1751.
209. Miyauchi Y., Michigami T., Sakaguchi N., Sekimoto T., Yoneda Y., Pike J.W., et al. Importin 4 is responsible for ligand-independent nuclear translocation of vitamin D receptor. J Biol Chem 2005, 280:40901-40908.
210. Levin A.A., Sturzenbecker L.J., Kazmer S., Bosakowski T., Huselton C., Allenby G., et al. 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha. Nature 1992, 355:359-361.
211. Heyman R.A., Mangelsdorf D.J., Dyck J.A., Stein R.B., Eichele G., Evans R.M., et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992, 68:397-406.
212. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell 1995, 83:841-850.
213. Haussler M.R., Whitfield G.K., Haussler C.A., Hsieh J., Thompson P.D., Selznick S.H., et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998, 13:325-349.
214. Pathrose P., Barmina O., Chang C.Y., McDonnell D.P., Shevde N.K., Pike J.W. Inhibition of 1,25-dihydroxyvitamin D3-dependent transcription by synthetic LXXLL peptide antagonists that target the activation domains of the vitamin D and retinoid X receptors. J Bone Miner Res 2002, 17:2196-2205.
215. Thompson P.D., Remus L.S., Hsieh J.C., Jurutka P.W., Whitfield G.K., Galligan M.A., et al. Distinct retinoid X receptor activation function-2 residues mediate transactivation in homodimeric and vitamin D receptor heterodimeric contexts. J Mol Endocrinol 2001, 27:211-227.
216. Bettoun D.J., Burris T.P., Houck K.A., Buck D.W., Stayrook K.R., Khalifa B., Lu J., Chin W.W., Nagpal S. Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation. Mol Endocrinol 2003, 17:2320-2328.
217. Kerner S.A., Scott R.A., Pike J.W. Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3. Proc Natl Acad Sci U S A 1989, 86:4455-4459.
218. Ozono K., Liao J., Kerner S.A., Scott R.A., Pike J.W. The vitamin D-responsive element in the human osteocalcin gene. Association with a nuclear proto-oncogene enhancer. J Biol Chem 1990, 265:21881-21888.
219. Carlberg C. Molecular basis of the selective activity of vitamin D analogues. J Cell Biochem 2003, 88:274-281.
220. Jin C.H., Kerner S.A., Hong M.H., Pike J.W. Transcriptional activation and dimerization functions in the human vitamin D receptor. Mol Endocrinol 1996, 10:945-957.
221. Murayama A., Kim M.S., Yanagisawa J., Takeyama K., Kato S. Transrepression by a liganded nuclear receptor via a bHLH activator through co-regulator switching. EMBO J 2004, 23:1598-1608.
222. Kim M.S., Fujiki R., Kitagawa H., Kato S. 1alpha,25(OH)2D3-induced DNA methylation suppresses the human CYP27B1 gene. Mol Cell Endocrinol 2007, 265-266:168-173.
223. Wang T.T., Tavera-Mendoza L.E., Laperriere D., Libby E., MacLeod N.B., Nagai Y., et al. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005, 19:2685-2695.
224. Pike J.W. Genome-wide principles of gene regulation by the vitamin D receptor and its activating ligand. Mol Cell Endocrinol 2011, 347:3-10.
225. Meyer M.B., Goetsch P.D., Pike J.W. A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1alpha,25-dihydroxyvitamin D3. J Biol Chem 2010, 285:15599-15610.
226. McKenna N.J., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999, 20:321-344.
227. Rachez C., Freedman L.P. Mechanisms of gene regulation by vitamin D(3) receptor: a network of coactivator interactions. Gene 2000, 246:9-21.
228. Robyr D., Wolffe A.P., Wahli W. Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol Endocrinol 2000, 14:329-347.
229. Feng W., Ribeiro R.C., Wagner R.L., Nguyen H., Apriletti J.W., Fletterick R.J., et al. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 1998, 280:1747-1749.
230. Rachez C., Suldan Z., Ward J., Chang C.P., Burakov D., Erdjument-Bromage H., et al. A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell- free system. Genes Dev 1998, 12:1787-1800.
231. Rachez C., Lemon B.D., Suldan Z., Bromleigh V., Gamble M., Naar A.M., et al. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 1999, 398:824-828.
232. Yamaoka K., Shindo M., Iwasaki K., Yamaoka I., Yamamoto Y., Kitagawa H., et al. Multiple co-activator complexes support ligand-induced transactivation function of VDR. Arch Biochem Biophys 2007, 460:166-171.
233. Kim S., Shevde N.K., Pike J.W. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts. J Bone Miner Res 2005, 20:305-317.
234. Baudino T.A., Kraichely D.M., Jefcoat S.C., Winchester S.K., Partridge N.C., MacDonald P.N. Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription. J Biol Chem 1998, 273:16434-16441.
235. Barry J.B., Leong G.M., Church W.B., Issa L.L., Eisman J.A., Gardiner E.M. Interactions of SKIP/NCoA-62, TFIIB, and retinoid X receptor with vitamin D receptor helix H10 residues. J Biol Chem 2003, 278:8224-8228.
236. MacDonald P.N., Dowd D.R., Zhang C., Gu C. Emerging insights into the coactivator role of NCoA62/SKIP in Vitamin D-mediated transcription. J Steroid Biochem Mol Biol 2004, 89-90:179-186.
237. Kato S., Fujiki R., Kitagawa H. Vitamin D receptor (VDR) promoter targeting through a novel chromatin remodeling complex. J Steroid Biochem Mol Biol 2004, 89-90:173-178.
238. Fujiki R., Kim M.S., Sasaki Y., Yoshimura K., Kitagawa H., Kato S. Ligand-induced transrepression by VDR through association of WSTF with acetylated histones. EMBO J 2005, 24:3881-3894.
239. Kitagawa H., Fujiki R., Yoshimura K., Oya H., Kato S. Williams syndrome is an epigenome-regulator disease. Endocr J 2011, 58:77-85.
240. Yen P.M., Liu Y., Sugawara A., Chin W.W. Vitamin D receptors repress basal transcription and exert dominant negative activity on triiodothyronine-mediated transcriptional activity. J Biol Chem 1996, 271:10910-10916.
241. Polly P., Herdick M., Moehren U., Baniahmad A., Heinzel T., Carlberg C. VDR-Alien: a novel, DNA-selective vitamin D(3) receptor-corepressor partnership. FASEB J 2000, 14:1455-1463.
242. Hsieh J.C., Sisk J.M., Jurutka P.W., Haussler C.A., Slater S.A., Haussler M.R., et al. Physical and functional interaction between the vitamin D receptor and hairless corepressor, two proteins required for hair cycling. J Biol Chem 2003, 278:38665-38674.
243. Xie Z., Chang S., Oda Y., Bikle D.D. Hairless suppresses vitamin D receptor transactivation in human keratinocytes. Endocrinology 2006, 147:314-323.
244. Malloy P.J., Wang J., Jensen K., Feldman D. Modulation of vitamin D receptor activity by the corepressor hairless: differential effects of hairless isoforms. Endocrinology 2009, 150:4950-4957.
245. Wang J., Malloy P.J., Feldman D. Interactions of the vitamin D receptor with the corepressor hairless: analysis of hairless mutants in atrichia with papular lesions. J Biol Chem 2007, 282:25231-25239.
246. Pike J.W. Genome-scale techniques highlight the epigenome and redefine fundamental principles of gene regulation. J Bone Miner Res 2011, 26:1155-1162.
247. Dowd D.R., MacDonald P.N. The 1,25-dihydroxyvitamin D3-independent actions of the vitamin D receptor in skin. J Steroid Biochem Mol Biol 2010, 121:317-321.
248. Bouillon R., Carmeliet G., Verlinden L., van Etten E., Verstuyf A., Luderer H.F., et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008, 29:726-776.
249. Malloy P.J., Xu R., Peng L., Clark P.A., Feldman D. A novel mutation in helix 12 of the vitamin D receptor impairs coactivator interaction and causes hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Mol Endocrinol 2002, 16:2538-2546.
250. Malloy P.J., Xu R., Peng L., Peleg S., Al-Ashwal A., Feldman D. Hereditary 1,25-dihydroxyvitamin D resistant rickets due to a mutation causing multiple defects in vitamin D receptor function. Endocrinology 2004, 145:5106-5114.
251. Malloy P.J., Xu R., Cattani A., Reyes L., Feldman D. A unique insertion/substitution in helix H1 of the vitamin D receptor ligand binding domain in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets. J Bone Miner Res 2004, 19:1018-1024.
252. Skorija K., Cox M., Sisk J.M., Dowd D.R., MacDonald P.N., Thompson C.C., et al. Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Mol Endocrinol 2005, 19:855-862.
253. Li X., Zheng W., Li Y.C. Altered gene expression profile in the kidney of vitamin D receptor knockout mice. J Cell Biochem 2003, 89:709-719.
254. Malloy P.J., Feldman D. The role of vitamin D receptor mutations in the development of alopecia. Mol Cell Endocrinol 2011, 347:90-96.
255. Alimirah, F., Vaishnav, A., McCormick, M., Echchgadda, I., Chatterjee, B., Mehta, R. G., and Peng, X. Functionality of unliganded VDR in breast cancer cells: repressive action on CYP24 basal transcription. Mol. Cell. Biochem. 342, 143-150.
256. Krishnan A.V., Feldman D. Regulation of vitamin D receptor abundance. Vitamin D 1997, 179-200. Academic Press, San Diego. 1st ed. D. Feldman, F.H. Glorieux, J.W. Pike (Eds.).
257. Esteban L., Eisman J., Gardiner E. Vitamin D receptor promoter and regulation of receptor expression. Vitamin D 2005, 193-217. Elsevier, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
258. Costa E.M., Hirst M.A., Feldman D. Regulation of 1,25-dihydroxyvitamin D3 receptors by vitamin D analogs in cultured mammalian cells. Endocrinology 1985, 117:2203-2210.
259. Costa E.M., Feldman D. Homologous up-regulation of the 1,25 (OH)2 vitamin D3 receptor in rats. Biochem Biophys Res Commun 1986, 137:742-747.
260. Favus M.J., Mangelsdorf D.J., Tembe V., Coe B.J., Haussler M.R. Evidence for in vivo upregulation of the intestinal vitamin D receptor during dietary calcium restriction in the rat. J Clin Invest 1988, 82:218-224.
261. Strom M., Sandgren M.E., Brown T.A., DeLuca H.F. 1,25-Dihydroxyvitamin D3 up-regulates the 1,25-dihydroxyvitamin D3 receptor in vivo. Proc Natl Acad Sci U S A 1989, 86:9770-9773.
262. Zhao X., Feldman D. Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. Endocrinology 1993, 132:1808-1814.
263. Wiese R.J., Uhland-Smith A., Ross T.K., Prahl J.M., DeLuca H.F. Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem 1992, 267:20082-20086.
264. Santiso-Mere D., Sone T., Hilliard G.M., Pike J.W., McDonnell D.P. Positive regulation of the vitamin D receptor by its cognate ligand in heterologous expression systems. Mol Endocrinol 1993, 7:833-839.
265. Arbour N.C., Prahl J.M., DeLuca H.F. Stabilization of the vitamin D receptor in rat osteosarcoma cells through the action of 1,25-dihydroxyvitamin D3. Mol Endocrinol 1993, 7:1307-1312.
266. Zella L.A., Meyer M.B., Nerenz R.D., Lee S.M., Martowicz M.L., Pike J.W. Multifunctional enhancers regulate mouse and human vitamin D receptor gene transcription. Mol Endocrinol 2010, 24:128-147.
267. Mohri T., Nakajima M., Takagi S., Komagata S., Yokoi T. MicroRNA regulates human vitamin D receptor. Int J Cancer 2009, 125:1328-1333.
268. Essa S., Denzer N., Mahlknecht U., Klein R., Collnot E.M., Tilgen W., et al. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells. J Steroid Biochem Mol Biol 2010, 121:110-113.
269. Narvaez C.J., Vanweelden K., Byrne I., Welsh J. Characterization of a vitamin D3-resistant MCF-7 cell line. Endocrinology 1996, 137:400-409.
270. Skowronski R.J., Peehl D.M., Feldman D. Actions of vitamin D3 analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology 1995, 136:20-26.
271. Yoshizawa T., Handa Y., Uematsu Y., Takeda S., Sekine K., Yoshihara Y., et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997, 16:391-396.
272. Erben R.G., Soegiarto D.W., Weber K., Zeitz U., Lieberherr M., Gniadecki R., et al. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol Endocrinol 2002, 16:1524-1537.
273. Li Y.C., Pirro A.E., Amling M., Delling G., Baron R., Bronson R., et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci U S A 1997, 94:9831-9835.
274. Amling M., Priemel M., Holzmann T., Chapin K., Rueger J.M., Baron R., et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 1999, 140:4982-4987.
275. Van Cromphaut S.J., Dewerchin M., Hoenderop J.G., Stockmans I., Van Herck E., Kato S., et al. Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci U S A 2001, 98:13324-13329.
276. 3 on voltage-sensitive calcium channels in the vitamin D endocrine system. Vitamin D 2005, 751-760. Elsevier, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
277. Mizwicki M.T., Menegaz D., Yaghmaei S., Henry H.L., Norman A.W. A molecular description of ligand binding to the two overlapping binding pockets of the nuclear vitamin D receptor (VDR): structure-function implications. J Steroid Biochem Mol Biol 2010, 121:98-105.
278. Menegaz D., Mizwicki M.T., Barrientos-Duran A., Chen N., Henry H.L., Norman A.W. Vitamin D receptor (VDR) regulation of voltage-gated chloride channels by ligands preferring a VDR-alternative pocket (VDR-AP). Mol Endocrinol 2011, 25:1289-1300.
279. Dixon K.M., Norman A.W., Sequeira V.B., Mohan R., Rybchyn M.S., Reeve V.E., et al. 1alpha,25(OH)-vitamin D and a nongenomic vitamin D analogue inhibit ultraviolet radiation-induced skin carcinogenesis. Cancer Prev Res (Phila) 2011, 4:1485-1494.
280. Nemere I., Farach-Carson M.C., Rohe B., Sterling T.M., Norman A.W., Boyan B.D., et al. Ribozyme knockdown functionally links a 1,25(OH)2D3 membrane binding protein (1,25D3-MARRS) and phosphate uptake in intestinal cells. Proc Natl Acad Sci U S A 2004, 101:7392-7397.
281. Sequeira V.B., Rybchyn M.S., Tongkao-On W., Gordon-Thomson C., Malloy P.J., Nemere I., et al. The role of the vitamin D receptor and ERp57 in photoprotection by 1alpha,25-dihydroxyvitamin D3. Mol Endocrinol 2012, 26:574-582.
282. Feldman D., Malloy P.J., Miller W.L. Genetic disorders of vitamin D synthesis and action. Genetics of Bone Biology and Skeletal Disease 2012, Elsevier/Academic Press. R.V. Thakker, M.P. Whyte, J.A. Eisman, T. Igarashi (Eds.).
283. Meir T., Levi R., Lieben L., Libutti S., Carmeliet G., Bouillon R., et al. Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the receptor in parathyroid physiology. Am J Physiol Renal Physiol 2009, 297:F1192-F1198.
284. Li W.F., Hou S.X., Yu B., Li M.M., Ferec C., Chen J.M. Genetics of osteoporosis: accelerating pace in gene identification and validation. Hum Genet 2010, 127:249-285.
285. Ralston S.H., Uitterlinden A.G. Genetics of osteoporosis. Endocr Rev 2010, 31:629-662.
286. Jones G. Vitamin D analogs. Endocrinol Metab Clin North Am 2010, 39:447-472.
287. Chiellini G., Rapposelli S., Zhu J., Massarelli I., Saraceno M., Bianucci A.M., et al. Synthesis and biological activities of vitamin D-like inhibitors of CYP24 hydroxylase. Steroids 2012, 77:212-223.
288. Kato Y., Nakano Y., Sano H., Tanatani A., Kobayashi H., Shimazawa R., et al. Synthesis of 1alpha,25-dihydroxyvitamin D3-26,23-lactams (DLAMs), a novel series of 1 alpha,25-dihydroxyvitamin D3 antagonist. Bioorg Med Chem Lett 2004, 14:2579-2583.
289. Ozono K., Saito M., Miura D., Michigami T., Nakajima S., Ishizuka S. Analysis of the molecular mechanism for the antagonistic action of a novel 1alpha,25-dihydroxyvitamin D(3) analogue toward vitamin D receptor function. J Biol Chem 1999, 274:32376-32381.
290. Fujishima T., Kojima Y., Azumaya I., Kittaka A., Takayama H. Design and synthesis of potent vitamin D receptor antagonists with A-ring modifications: remarkable effects of 2alpha-methyl introduction on antagonistic activity. Bioorg Med Chem 2003, 11:3621-3631.
291. Mizwicki M.T., Bula C.M., Mahinthichaichan P., Henry H.L., Ishizuka S., Norman A.W. On the mechanism underlying (23S)-25-dehydro-1alpha(OH)-vitamin D3-26,23-lactone antagonism of hVDRwt gene activation and its switch to a superagonist. J Biol Chem 2009, 284:36292-36301.
292. Kakuda S., Ishizuka S., Eguchi H., Mizwicki M.T., Norman A.W., Takimoto-Kamimura M. Structural basis of the histidine-mediated vitamin D receptor agonistic and antagonistic mechanisms of (23S)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone. Acta Crystallogr D Biol Crystallogr 2010, 66:918-926.
293. Heaney R.P. Vitamin D: role in the calcium economy. Vitamin D 2005, 773-787. Elsevier, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
294. Carmeliet G., Van Cromphaut S., Daci E., Maes C., Bouillon R. Disorders of calcium homeostasis. Best Pract Res Clin Endocrinol Metab 2003, 17:529-546.
295. Kolek O.I., Hines E.R., Jones M.D., LeSueur L.K., Lipko M.A., Kiela P.R., et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005, 289:G1036-G1042.
296. Hines E.R., Kolek O.I., Jones M.D., Serey S.H., Sirjani N.B., Kiela P.R., et al. 1,25-dihydroxyvitamin D3 down-regulation of PHEX gene expression is mediated by apparent repression of a 110 kDa transfactor that binds to a polyadenine element in the promoter. J Biol Chem 2004, 279:46406-46414.
297. Nagai R., Saito Y., Ohyama Y., Aizawa H., Suga T., Nakamura T., et al. Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci 2000, 57:738-746.
298. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004, 113:561-568.
299. Haussler M.R., Whitfield G.K., Kaneko I., Forster R., Saini R., Hsieh J.C., et al. The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord 2012, 13:57-69.
300. Christakos S. Recent advances in our understanding of 1,25-dihydroxyvitamin D(3) regulation of intestinal calcium absorption. Arch Biochem Biophys 2012, 523:73-76.
301. Fleet J.C., Schoch R.D. Molecular mechanisms for regulation of intestinal calcium absorption by vitamin D and other factors. Crit Rev Clin Lab Sci 2010, 47:181-195.
302. Hoenderop J.G., Nilius B., Bindels R.J. Calcium absorption across epithelia. Physiol Rev 2005, 85:373-422.
303. Wasserman R.H. Vitamin D and the intestial absorption of calcium: a view and overview. Vitamin D 2005, 411-428. Elsevier, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
304. Hoenderop J.G., Dardenne O., Van Abel M., Van Der Kemp A.W., Van Os C.H., St -Arnaud R., et al. Modulation of renal Ca2+ transport protein genes by dietary Ca2+ and 1,25-dihydroxyvitamin D3 in 25-hydroxyvitamin D3-1alpha-hydroxylase knockout mice. FASEB J 2002, 16:1398-1406.
305. Norman A.W. Vitamin D receptor (VDR): new assignments for an already busy receptor. Endocrinology 2006, 147:5542-5548.
306. Horst R.L., Goff J.P., Reinhardt T.A. Advancing age results in reduction of intestinal and bone 1,25-dihydroxyvitamin D receptor. Endocrinology 1990, 126:1053-1057.
307. Liang C.T., Barnes J., Imanaka S., DeLuca H.F. Alterations in mRNA expression of duodenal 1,25-dihydroxyvitamin D3 receptor and vitamin D-dependent calcium binding protein in aged Wistar rats. Exp Gerontol 1994, 29:179-186.
308. Colin E.M., Van Den Bemd G.J., Van Aken M., Christakos S., De Jonge H.R., Deluca H.F., et al. Evidence for involvement of 17beta-estradiol in intestinal calcium absorption independent of 1,25-dihydroxyvitamin D3 level in the Rat. J Bone Miner Res 1999, 14:57-64.
309. Rubin M.R., Thys-Jacobs S., Chan F.K.W., Koberle L.M.C., Bilezikian J.P. Hypercalcemia due to vitamin D toxicity. Vitamin D 2005, 1355-1377. Elsevier, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
310. Barbour G.L., Coburn J.W., Slatopolsky E., Norman A.W., Horst R.L. Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N Engl J Med 1981, 305:440-443.
311. Siltzbach L.E., James D.G., Neville E., Turiaf J., Battesti J.P., Sharma O.P., et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974, 57:847-852.
312. Seymour J.F., Gagel R.F. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993, 82:1383-1394.
313. Hewison M., Kantorovich V., Liker H.R., Van Herle A.J., Cohan P., Zehnder D., et al. Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J Bone Miner Res 2003, 18:579-582.
314. Kumar R., Cohen W.R., Silva P., Epstein F.H. Elevated 1,25-dihydroxyvitamin D plasma levels in normal human pregnancy and lactation. J Clin Invest 1979, 63:342-344.
315. Bikle D.D., Gee E., Halloran B., Haddad J.G. Free 1,25-dihydroxyvitamin D levels in serum from normal subjects, pregnant subjects, and subjects with liver disease. J Clin Invest 1984, 74:1966-1971.
316. Cheema C., Grant B.F., Marcus R. Effects of estrogen on circulating "free" and total 1,25-dihydroxyvitamin D and on the parathyroid-vitamin D axis in postmenopausal women. J Clin Invest 1989, 83:537-542.
317. Vargas S., Bouillon R., Van Baelen H., Raisz L.G. Effects of vitamin D-binding protein on bone resorption stimulated by 1,25 dihydroxyvitamin D3. Calcif Tissue Int 1990, 47:164-168.
318. Thiex N.W., Kalkwarf H.J., Specker B.L. Vitamin D metabolism in pregnancy and lactation. Vitamin D 2011, Elsevier/Academic Press, San Diego, 679-674. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
319. Bai S., Wang H., Shen J., Zhou R., Bushinsky D.A., Favus M.J. Elevated vitamin D receptor levels in genetic hypercalciuric stone-forming rats are associated with downregulation of Snail. J Bone Miner Res 2010, 25:830-840.
320. Larriba M.J., Bonilla F., Munoz A. The transcription factors Snail1 and Snail2 repress vitamin D receptor during colon cancer progression. J Steroid Biochem Mol Biol 2010, 121:106-109.
321. Pena C., Garcia J.M., Larriba M.J., Barderas R., Gomez I., Herrera M., et al. SNAI1 expression in colon cancer related with CDH1 and VDR downregulation in normal adjacent tissue. Oncogene 2009, 28:4375-4385.
322. Bai S., Favus M.J. Vitamin D and calcium receptors: links to hypercalciuria. Curr Opin Nephrol Hypertens 2006, 15:381-385.
323. Franceschi R.T., Li Y. Vitamin D regulation of osteoblast function. Vitamin D 2011, 321-334. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
324. Lian J.B., Stein G.S., Montecino M., Stein J.L., van Wijnen A. Genetic and epigenetic control of the regulatory machinary for skeletal develpment and bone formation: contributions of vitamin D3. Vitamin D 2011, 301-320. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
325. Terpening C.M., Haussler C.A., Jurutka P.W., Galligan M.A., Komm B.S., Haussler M.R. The vitamin D-responsive element in the rat bone Gla protein gene is an imperfect direct repeat that cooperates with other cis-elements in 1,25-dihydroxyvitamin D3-mediated transcriptional activation. Mol Endocrinol 1991, 5:373-385.
326. Hauschka P.V., Lian J.B., Cole D.E., Gundberg C.M. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 1989, 69:990-1047.
327. Fukumoto S., Martin T.J. Bone as an endocrine organ. Trends Endocrinol Metab 2009, 20:230-236.
328. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130:456-469.
329. Weissen-Plenz G., Nitschke Y., Rutsch F. Mechanisms of arterial calcification: spotlight on the inhibitors. Adv Clin Chem 2008, 46:263-293.
330. Barthel T.K., Mathern D.R., Whitfield G.K., Haussler C.A., Hopper H.A., Hsieh J.C., Slater S.A., Hsieh G., Kaczmarska M., Jurutka P.W., Kolek O.I., et al. 1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol 2007, 103:381-388.
331. Fretz J.A., Zella L.A., Kim S., Shevde N.K., Pike J.W. 1,25-Dihydroxyvitamin D3 regulates the expression of LDL receptor-related protein 5 via DNA sequence elements located downstream of the start site of transcription. Mol Endocrinol 2006, 20:2215-2230.
332. Milat F., Ng K.W. Is Wnt signalling the final common pathway leading to bone formation?. Mol Cell Endocrinol 2009, 310:52-62.
333. Larriba M.J., Ordonez-Moran P., Chicote I., Martin-Fernandez G., Puig I., Munoz A., et al. Vitamin D receptor deficiency enhances Wnt/beta-catenin signaling and tumor burden in colon cancer. PLoS One 2011, 6:e23524.
334. Pendas-Franco N., Aguilera O., Pereira F., Gonzalez-Sancho J.M., Munoz A. Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. AntiCancer Res 2008, 28:2613-2623.
335. Panda D.K., Miao D., Bolivar I., Li J., Huo R., Hendy G.N., et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004, 279:16754-16766.
336. Goltzman D. Emerging roles for calcium-regulating hormones beyond osteolysis. Trends Endocrinol Metab 2010, 21:512-518.
337. Raisz L.G., Trummel C.L., Holick M.F., DeLuca H.F. 1,25-dihydroxycholecalciferol: a potent stimulator of bone resorption in tissue culture. Science 1972, 175:768-769.
338. Stern P.H. Bone. Vitamin D 2005, 565-573. Elsevier, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
339. Kitazawa R., Kitazawa S. Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun 2002, 290:650-655.
340. Fu Q., Manolagas S.C., O'Brien C.A. Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol 2006, 26:6453-6468.
341. Martowicz M.L., Meyer M.B., Pike J.W. The mouse RANKL gene locus is defined by a broad pattern of histone H4 acetylation and regulated through distinct distal enhancers. J Cell Biochem 2011, 112:2030-2045.
342. Haussler M.R., Haussler C.A., Whitfield G.K., Hsieh J.C., Thompson P.D., Barthel T.K., et al. The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the "Fountain of Youth" to mediate healthful aging. J Steroid Biochem Mol Biol 2010, 121:88-97.
343. Baldock P.A., Thomas G.P., Hodge J.M., Baker S.U., Dressel U., O'Loughlin P.D., Nicholson G.C., Briffa K.H., Eisman J.A., Gardiner E.M. Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast. J Bone Miner Res 2006, 21:1618-1626.
344. Bergwitz C., Juppner H. FGF23 and syndromes of abnormal renal phosphate handling. Adv Exp Med Biol 2012, 728:41-64.
345. Damasiewicz M.J., Toussaint N.D., Polkinghorne K.R. Fibroblast growth factor 23 in chronic kidney disease: new insights and clinical implications. Nephrology (Carlton) 2011, 16:261-268.
346. Brown A.J., Slatopolsky E.A. Mechanisms for the selective actions of vitamin D analogs. Vitamin D 2005, 1449-1469. Elsevier, San Diego. 2nd ed. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
347. Chakravarti B., Chattopadhyay N., Brown E.M. Signaling through the extracellular calcium-sensing receptor (CaSR). Adv Exp Med Biol 2012, 740:103-142.
348. Cozzolino M., Brandenburg V. Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U". Clin Nephrol 2009, 71:593-601.
349. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003, 349:446-456.
350. Melamed M.L., Thadhani R.I. Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol 2012, 7:358-365.
351. Cheng J., Zhang W., Zhang X., Li X., Chen J. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2012, 7:391-400.
352. Canaff L., Hendy G.N. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 2002, 277:30337-30350.
353. Rao D.S., Honasoge M., Divine G.W., Phillips E.R., Lee M.W., Ansari M.R., et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 2000, 85:1054-1058.
354. Slatopolsky E. The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney Int Suppl 2011, S3-S8.
355. Fokuda N., Tanaka H., Tominaga Y., Fukagawa M., Kurokawa K., Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993, 92:1436-1443.
356. Feldman D. Vitamin D, parathyroid hormone, and calcium: a complex regulatory network. Am J Med 1999, 107:637-639.
357. Grey A., Lucas J., Horne A., Gamble G., Davidson J.S., Reid I.R. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 2005, 90:2122-2126.
358. Li Y.C. Vitamin D: roles in renal and cardiovascular protection. Curr Opin Nephrol Hypertens 2012, 21:72-79.
359. Shroff R., Wan M., Gullett A., Ledermann S., Shute R., Knott C., et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol 2012, 7:216-223.
360. Cantorna M.T. Vitamin D, multiple sclerosis and inflammatory bowel disease. Arch Biochem Biophys 2012, 523:103-106.
361. Chun R.F., Adams J.S., Hewison M. Immunomodulation by vitamin D: implications for TB. Exp Rev Clin Pharmacol 2011, 4:583-591.
362. Harms L.R., Burne T.H., Eyles D.W., McGrath J.J. Vitamin D and the brain. Best Pract Res Clin Endocrinol Metab 2011, 25:657-669.
363. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf) 2012, 76:315-325.
364. Krishnan A.V., Trump D.L., Johnson C.S., Feldman D. The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am 2010, 39:401-418.
365. McGreevy C., Williams D. New insights about vitamin D and cardiovascular disease: a narrative review. Ann Intern Med 2011, 155:820-826.
366. Mitri J., Muraru M.D., Pittas A.G. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr 2011, 65:1005-1015.
367. O'Keefe J.H., Lavie C.J., Holick M.F. Vitamin D supplementation for cardiovascular disease prevention. JAMA 2011, 306:1546-1547.
368. Takiishi T., Gysemans C., Bouillon R., Mathieu C. Vitamin D and diabetes. Endocrinol Metab Clin North Am 2010, 39:419-446.
369. Vaidya A., Williams J.S. The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Metabolism 2012, 61:450-458.
370. Vanoirbeek E., Krishnan A., Eelen G., Verlinden L., Bouillon R., Feldman D., et al. The anti-cancer and anti-inflammatory actions of 1,25(OH)D. Best Pract. Res. Clin. Endocrinol. Metab 2011, 25:593-604.
371. Welsh J. Cellular and molecular effects of vitamin D on carcinogenesis. Arch Biochem Biophys 2012, 523:107-114.
372. Giovannucci E. Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol 2008, 624:31-42.
373. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005, 16:83-95.
374. Garland C.F., Garland F.C., Gorham E.D., Lipkin M., Newmark H., Mohr S.B., et al. The role of vitamin D in cancer prevention. Am J Public Health 2006, 96:252-261.
375. Giovannucci E., Liu Y., Rimm E.B., Hollis B.W., Fuchs C.S., Stampfer M.J., et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006, 98:451-459.
376. Yin L., Grandi N., Raum E., Haug U., Arndt V., Brenner H. Meta-analysis: serum vitamin D and colorectal adenoma risk. Prev Med 2011, 53:10-16.
377. Yin L., Grandi N., Raum E., Haug U., Arndt V., Brenner H. Meta-analysis: serum vitamin D and breast cancer risk. Eur. J Cancer 2010, 46:2196-2205.
378. Shui I.M., Mucci L.A., Kraft P., Tamimi R.M., Lindstrom S., Penney K.L., et al. Vitamin D-related genetic variation, plasma vitamin d, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst 2012, 104:690-699.
379. Moreno J., Krishnan A.V., Swami S., Nonn L., Peehl D.M., Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005, 65:7917-7925.
380. Nonn L., Peng L., Feldman D., Peehl D.M. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res 2006, 66:4516-4524.
381. Chen Y., Kong J., Sun T., Li G., Szeto F.L., Liu W., et al. 1,25-Dihydroxyvitamin D suppresses inflammation-induced expression of plasminogen activator inhibitor-1 by blocking nuclear factor-kappaB activation. Arch Biochem Biophys 2011, 507:241-247.
382. Krishnan A.V., Swami S., Feldman D. Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling. J Steroid Biochem Mol Biol 2010, 121:343-348.
383. Swami S., Krishnan A.V., Wang J.Y., Jensen K., Peng L., Albertelli M.A., et al. Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo. Horm Cancer 2011, 2:190-202.
384. Fleet J.C., DeSmet M., Johnson R., Li Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem J 2012, 441:61-76.
385. Maund S.L., Barclay W.W., Hover L.D., Axanova L.S., Sui G., Hipp J.D., et al. Interleukin-1alpha mediates the antiproliferative effects of 1,25-dihydroxyvitamin D3 in prostate progenitor/stem cells. Cancer Res 2011, 71:5276-5286.
386. So J.Y., Lee H.J., Smolarek A.K., Paul S., Wang C.X., Maehr H., et al. A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. Mol Pharmacol 2011, 79:360-367.
387. Fedirko V., Bostick R.M., Flanders W.D., Long Q., Sidelnikov E., Shaukat A., et al. Effects of vitamin D and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2009, 18:2933-2941.
388. Peng X., Hawthorne M., Vaishnav A., St-Arnaud R., Mehta R.G. 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res Treat 2009, 113:31-41.
389. Albertson D.G., Ylstra B., Segraves R., Collins C., Dairkee S.H., Kowbel D., et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000, 25:144-146.
390. Anderson M.G., Nakane M., Ruan X., Kroeger P.E., Wu-Wong J.R. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 2006, 57:234-240.
391. Friedrich M., Rafi L., Mitschele T., Tilgen W., Schmidt W., Reichrath J. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res 2003, 164:239-246.
392. Muindi J.R., Nganga A., Engler K.L., Coignet L.J., Johnson C.S., Trump D.L. CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines. J Steroid Biochem Mol Biol 2007, 103:334-337.
393. Komagata S., Nakajima M., Takagi S., Mohri T., Taniya T., Yokoi T. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol 2009, 76:702-709.
394. Luo W., Karpf A.R., Deeb K.K., Muindi J.R., Morrison C.D., Johnson C.S., et al. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res 2010, 70:5953-5962.
395. Liu P.T. The role of vitamin D in innate immunity: antibacterial activity, oxidative stress and barrier function. Vitamin D 2011, 1811-1824. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
396. White J.H. Vitamin D and innate immunity. Vitamin D 2011, 1777-1787. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
397. Hewison M. Antibacterial effects of vitamin D. Nat Rev Endocrinol 2011, 7:337-345.
398. Van Belle T.L., Gysemans C., Mathieu C. Vitamin D in autoimmune, infectious and allergic diseases: a vital player?. Best Pract Res Clin Endocrinol Metab 2011, 25:617-632.
399. White J.H. Vitamin D as an inducer of cathelicidin antimicrobial peptide expression: past, present and future. J Steroid Biochem Mol Biol 2010, 121:234-238.
400. Adorini L. Control of adaptive immunity by vitamin D receptor. Vitamin D 2011, 1789-1810. Elsevier/Academic Press, San Diego. 3rd ed. D. Feldman, J.W. Pike, J.S. Adams (Eds.).
401. Kamangar F., Isip L., Bhutani T., Dennis M., Heller M.M., Lee E.S., et al. How psoriasis patients perceive, obtain, and use biologic agents: survey from an academic medical center. J Dermatolog Treat 2013, 24:13-24.
402. Pittas A.G., Dawson-Hughes B. Vitamin D and diabetes. J Steroid Biochem Mol Biol 2010, 121:425-429.
403. Pilz S., Tomaschitz A. Role of vitamin D in arterial hypertension. Expert Rev Cardiovasc Ther 2010, 8:1599-1608.
404. Binkley N., Ramamurthy R., Krueger D. Low vitamin D status: definition, prevalence, consequences, and correction. Endocrinol Metab Clin North Am 2010, 39:287-301.
405. Hanley D.A., Cranney A., Jones G., Whiting S.J., Leslie W.D., Cole D.E., et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ 2010, 182:E610-E618.
406. Lips P., Bouillon R., van Schoor N.M., Vanderschueren D., Verschueren S., Kuchuk N., et al. Reducing fracture risk with calcium and vitamin D. Clin Endocrinol (Oxf) 2010, 73:277-285.
407. Peppone L.J., Hebl S., Purnell J.Q., Reid M.E., Rosier R.N., Mustian K.M., et al. The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review. Osteoporos Int 2010, 21:1133-1149.
408. Rosen C.J., Gallagher J.C. The 2011 IOM report on vitamin D and calcium requirements for north america: clinical implications for providers treating patients with low bone mineral density. J Clin Densitom 2011, 14:79-84.
409. Lips P., van Schoor N.M. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab 2011, 25:585-591.
410. Murad M.H., Elamin K.B., Abu Elnour N.O., Elamin M.B., Alkatib A.A., Fatourechi M.M., et al. Clinical review: the effect of vitamin D on falls: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011, 96:2997-3006.